logo
Study slices and dices the complex history of the modern strawberry

Study slices and dices the complex history of the modern strawberry

Yahoo6 hours ago

If you eat fruits or vegetables, how often do you think about their history? Former University of Florida post-doctoral researcher Zhen Fan did, as he traced the strawberry back over centuries.
In a new paper published in the Proceedings of the National Academy of Sciences, Fan, now a faculty member at Zhejiang Agriculture and Forestry University in China, examined the ancient origins of strawberry chromosomes.Modern strawberries have eight sets of chromosomes, making them what scientists call 'octoploids.' By comparison, most species, including humans, have two sets of chromosomes: they're diploids.
'The modern strawberry has about four times as much DNA as the most ancient wild strawberries,' said Vance Whitaker, a UF/IFAS professor of horticultural sciences, Fan's former supervisor and a corresponding author of the paper. 'This happened through hybridization (crossing) of up to four distinct wild species over a long time.'
'But this history and the identity of each of these ancient species have been difficult to trace because some of them went extinct long ago, and we can't study them directly,' said Whitaker, a strawberry breeder at the Gulf Coast Research and Education Center.
In the new study, Fan found an approach to better trace that history and, in the process, he found that, before the modern strawberry began to form, various types of ancient species crossed with each other.
'This means that the genetic background of the modern strawberry is even more complex than we thought,' Whitaker said.
'One reason this is important is that one day, we would like to reconstruct the modern strawberry from simpler species by making the crosses ourselves, and better understanding how the strawberry formed will help us do that,' Whitaker said. 'This could help us to breed better strawberry varieties in the future that are more genetically diverse and more resistant to pests and diseases.'
Strawberry is kind of the opposite of a 'purebred,' Whitaker said.
'With multiple species in its background the strawberry is fun and challenging to work with for a breeder like me,' he said.
Doug and Pam Soltis, distinguished professors at the Florida Museum of Natural History and co-authors on the study, put the research into an interesting historical perspective.
'Strawberry might be the opposite of a purebred, but it is typical of the complexities we see in natural populations of plants — complicated evolutionary histories of repeated hybridization, introgression and genome doubling,' Doug Soltis said. 'Solving these problems involves dedicated research — each is a story of intrigue and investigation that puts solving any murder mystery to shame.'
Added Pam Soltis: 'The methods developed for reconstructing the evolutionary history of strawberries may be useful in other crops where the ancestry is also uncertain. Polyploidy (more than two sets of chromosomes) is very common in wild plants — and occurs in other organisms as well, and I look forward to applying these methods to the study of wild polyploid species for which we know almost nothing about their evolutionary history.'
This article originally appeared on Tallahassee Democrat: Study slices into the complex history of modern strawberry

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Annals of Family Medicine: Body Fat Percentage Beats BMI in Predicting 15-Year Mortality Risk Among U.S. Adults Ages 20 to 49
Annals of Family Medicine: Body Fat Percentage Beats BMI in Predicting 15-Year Mortality Risk Among U.S. Adults Ages 20 to 49

Yahoo

time3 hours ago

  • Yahoo

Annals of Family Medicine: Body Fat Percentage Beats BMI in Predicting 15-Year Mortality Risk Among U.S. Adults Ages 20 to 49

PROVIDENCE, R.I., June 25, 2025 /PRNewswire/ -- A new study published in Annals of Family Medicine finds that body-fat percentage is a stronger predictor of 15-year mortality risk in U.S. adults than body mass index (BMI). Although BMI is widely used in clinics as the standard measure of body composition, it can potentially misclassify muscular individuals as overweight and miss cases of "normal-weight obesity," masking serious metabolic and heart disease risks. The study findings support reexamining how body composition is measured in clinical settings. Researchers from the University of Florida analyzed data from 4,252 participants in the 1999-2004 National Health and Nutrition Examination Survey (NHANES), a nationally representative sample of non-institutionalized U.S. adults ages 20 to 49. All participants had complete technician measured body composition data, including height, weight and waist circumference. Body fat percentage was assessed by bioelectrical impedance analysis. Records were linked to the National Death Index through 2019. After adjusting for age, race and poverty status, the study found: Numbers in parentheses are the hazard ratio (HR) and its 95% confidence interval (CI). Adults with a high body-fat percentage (27% or more in men; 44% or more in women) were 1.78 times more likely to die from any cause than individuals in the healthy body fat range (HR 1.78; 95% CI, 1.28 to 2.47). Adults with a high body-fat percentage were also 3.62 times more likely to die from heart disease (HR 3.62; 95% CI, 1.55 to 8.45). Overweight/obese BMI (25 kg/m² or higher) was not associated with a statistically significant higher risk of death from any cause, compared with adults in the healthy BMI range (HR 1.25, 95% CI 0.85 to 1.84). Adults with a high waist circumference (more than 40 inches in men; more than 35 inches in women) were 1.59 times more likely to die from any cause than individuals in the healthy range (HR 1.59; 95% CI, 1.12 to 2.26). Adults with a high waist circumference were also 4.01 times more likely to die from heart disease (HR 4.01; 95% CI, 1.94 to 8.27). Historically, it has been difficult to measure body fat percentage in primary care outpatient settings. New bioelectrical impedance devices have the potential to change this; however, implementation details remain to be worked out, as primary care clinics are not yet routinely using them. "This is a game changer for body composition assessment. Our study is basically a Coke versus Pepsi comparison of a direct and indirect measure of body fat for future mortality risk and a direct measure of body fat percentage that can be done in the office was significantly better," said Arch G. Mainous III, PhD, lead author and professor in the Department of Health Services Research, Management and Policy at the University of Florida. "The medical community has been aware that BMI has some limitations as a measure of body composition and disease risk. It is an indirect measure of body fat percentage. Direct measures have historically been too expensive and difficult to use in the office. Our study shows that a direct measure of body fat that can be done easily, practically and inexpensively in a doctor's office solves the problems of BMI," said Frank A. Orlando, MD, corresponding author in the Department of Community Health and Family Medicine at the University of Florida. Article Cited: Body Mass Index vs Body Fat Percentage as a Predictor of Mortality in Adults Aged 20-49 Years Arch G. Mainous III, PhD; Lu Yin, PhD; Velyn Wu, MD, MACM; Pooja Sharma, MPH; Breana M. Jenkins, BPH; Aaron A. Saguil, MD, MPH; Danielle S. Nelson, MD, MPH; and Frank A. Orlando, MD Annals of Family Medicine is an open access, peer-reviewed, indexed research journal that provides a cross-disciplinary forum for new, evidence-based information affecting the primary care disciplines. Launched in May 2003, Annals of Family Medicine is sponsored by six family medical organizations, including the American Academy of Family Physicians, the American Board of Family Medicine, the Society of Teachers of Family Medicine, the Association of Departments of Family Medicine, the Association of Family Medicine Residency Directors, and the North American Primary Care Research Group. Annals of Family Medicine is published online six times each year, charges no fee for publication, and contains original research from the clinical, biomedical, social, and health services areas, as well as contributions on methodology and theory, selected reviews, essays, and editorials. Complete editorial content and interactive discussion groups for each published article can be accessed for free on the journal's website, View original content to download multimedia: SOURCE Annals of Family Medicine Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Global Drug Development Shifts East
Global Drug Development Shifts East

Forbes

time4 hours ago

  • Forbes

Global Drug Development Shifts East

Global clinical research The pharmaceutical industry is experiencing its own 'DeepSeek moment,' according to science writer Hiya Jain. Just as the upstart AI breakthrough caught Silicon Valley off-guard, China is emerging as a formidable force in drug development, fundamentally altering the global landscape of medical innovation. The numbers tell a remarkable story of transformation. In 2017, there were just over 600 clinical trials initiated in China. By 2023, that number was nearly 2,000. This tripling of clinical trial activity represents more than statistical growth—it signals a seismic shift in how and where the world's most critical medical breakthroughs are being developed. New Pharmaceutical Reality Today's pharmaceutical giants are increasingly looking East for their next breakthrough molecules. Large pharmaceutical companies in-license about a third of their experimental molecules from Chinese laboratories, a dramatic increase from just 10 percent a few years ago according to Stifel. This shift represents a fundamental reordering of the global pharmaceutical ecosystem, where 'Chinese companies will often run the phase I trial in China for cheap, then flip it to a Western pharmaceutical company to run the expensive US trials and bring the drug to market,' blogs biotech writer Alex Telford. The implications extend far beyond cost savings. About one-fourth of all clinical trials and early drug development now happens in China. This concentration of activity in a single nation represents a strategic vulnerability for Western pharmaceutical companies while simultaneously demonstrating China's growing dominance in the sector. According to World Health Organization data, since 2016, the Western Pacific region has been the region with the highest number of trial registration per year among WHO regions, driven primarily by China's explosive growth in clinical trial activity. The WHO reports that in 2023 the number of trials registered in Western Pacific (23,250) was around 14 times higher than that in Africa (845), highlighting the concentration of pharmaceutical development resources in developed and rapidly developing economies. The Policy Revolution Behind the Numbers China's pharmaceutical ascension didn't happen by accident—it was engineered through deliberate policy reforms that removed regulatory bottlenecks and streamlined approval processes. The transformation began in earnest around 2017 when Chinese regulators implemented several game-changing measures, writes Jain. The most significant was the introduction of an 'implied license' policy, which automatically authorizes a clinical trial if regulators voice no objections within 60 days. This eliminated the bureaucratic delays that had previously hampered drug development in the country. Simultaneously, China joined the International Council for Harmonisation (ICH) and began accepting overseas clinical trial data, reducing the need for companies to duplicate studies within Chinese borders. These reforms created a regulatory environment that prioritized speed without compromising safety. Drugs that qualify for priority review often address a critical, unmet clinical need, allowing them to go through an accelerated evaluation timeline. The result was a dramatic improvement in China's attractiveness as a location for pharmaceutical development. The policy changes also attracted international investment, creating a virtuous cycle of capital, expertise, and innovation. This influx of resources further accelerated China's biotech boom, establishing the country as a legitimate competitor to traditional pharmaceutical powerhouses in the United States and Europe. Quality Meets Quantity Critics might argue that China's rapid expansion in clinical trials represents quantity over quality, but the evidence suggests otherwise. The number of original, new drugs originating in China has climbed from almost zero in 2010 to a figure, in 2023, that approaches American totals. This isn't merely about conducting more trials—it's about developing genuinely innovative treatments. The quality of Chinese clinical trials is further evidenced by their enrollment rates. While over three-quarters of recent trials now enroll fewer than 100 participants in the United States, often due to recruitment difficulties, more than 40 percent of clinical trials in China have high enrollment levels. This superior enrollment capability translates to more robust data and faster progression through development phases. China's success in clinical trial recruitment stems from several advantages. The country has 'a wealth of treatment-naïve patients in therapeutic areas where U.S. trials struggle to recruit, including immune-oncology, NASH, chronic diseases, and many orphan indications' concentrated in top urban medical centers with costs that are 30 percent lower than in the United States, leading to patient recruitment that is 2-3 times faster. Medicine world map American Plateau While China has been ascending, the United States appears to have reached a plateau. In the early 2010s, the number of clinical trials performed by American companies increased steadily but then leveled out at about 1,900 studies each year. This stagnation comes at a time when medical needs are growing and pharmaceutical innovation is more critical than ever. The plateau reflects systemic challenges within the American pharmaceutical development system. Regulatory complexity, recruitment difficulties, and institutional red tape have created barriers that slow the translation of scientific discoveries into life-saving treatments. Examples include trial for lung cancer was forced to curtail its enrollment by half due to 'slow accrual' illustrate the real-world consequences of these systemic inefficiencies. The contrast with China's trajectory is stark. While American pharmaceutical development exhibits signs of institutional sclerosis, China's system demonstrates the power of aligned incentives, streamlined processes, and strategic coordination between regulatory bodies, research institutions, and industry players. Global Implications and Competitive Response China's rise in pharmaceutical development isn't occurring in isolation. South-East Asia is quickly growing in number of reported clinical trials and was the only region not to see a decrease since the peak of trials during the COVID-19 pandemic, driven largely by trials in India, where 90 percent of the region's trials are conducted. Other Asian nations are following China's example, implementing similar regulatory reforms to attract pharmaceutical development activity. Japan, South Korea, and India are all working to position themselves as attractive destinations for clinical trials and drug development, creating a competitive dynamic that benefits global pharmaceutical innovation. The WHO data reveals that between 2020 and 2023 the number of trials registered in lower middle income countries continued to rise by 36% compared to a 4% and 12% decrease in upper middle income and high income countries respectively. This trend suggests that pharmaceutical development is becoming increasingly democratized, with emerging economies playing larger roles in bringing new treatments to market. World Health Organization (WHO) (Photo by FABRICE COFFRINI/AFP via Getty Images) The Path Forward for America The United States isn't destined to cede pharmaceutical leadership to China, but action is required. Proposals from The Clinical Trial Abundance Initiative demonstrate that reform is possible, focusing on democratizing clinical research through expanded Medicaid coverage for trial participants, simplified paperwork, and fair compensation for participants. However, these reforms face significant political and institutional obstacles. Funding constraints and polarized attitudes toward agencies like the NIH and FDA complicate efforts to implement necessary changes. The challenge is compounded by America's fragmented healthcare system, which creates additional barriers to efficient clinical trial conduct. The contrast with China's approach is instructive. While American reforms must navigate complex federal systems and competing interests, China's centralized coordination, streamlined approval pathways, and top-down incentives for hospital participation have proven remarkably effective. Though different in method, both models show how aligning regulatory structures with participation incentives can unlock trial capacity and volume at scale. New Era of Pharmaceutical Geopolitics China's emergence as a pharmaceutical superpower represents more than a shift in market dynamics—it signals a new era of pharmaceutical geopolitics. The country that controls the development of life-saving treatments wields significant influence over global health outcomes and economic competitiveness. For pharmaceutical companies, the rise of China presents both opportunities and challenges. Access to Chinese markets, research capabilities, and patient populations offers tremendous potential for innovation and growth. However, dependence on Chinese infrastructure and expertise also creates strategic vulnerabilities, particularly in an era of increasing geopolitical tensions. The future of pharmaceutical development will likely be shaped by how Western nations respond to China's challenge. Countries that adapt their frameworks to expedite start-up times, recognize credible foreign data, and balance oversight with innovation-friendly policies will be best positioned to capture the next wave of drug discoveries. The pharmaceutical industry's shifts are a wake-up call for American policymakers and business leaders. Asia's rapid ascension in drug development demonstrates that regulatory reform, strategic coordination, and sustained investment can dramatically accelerate medical innovation. The question now is whether the United States will learn from China's example and implement the reforms necessary to maintain its position as a global leader in pharmaceutical development.

2025 China Energy Internet Conference Wraps Up in Hangzhou
2025 China Energy Internet Conference Wraps Up in Hangzhou

Yahoo

time5 hours ago

  • Yahoo

2025 China Energy Internet Conference Wraps Up in Hangzhou

HANGZHOU, China, June 25, 2025 /PRNewswire/ -- 2025 China Energy Internet Conference wrapped up in Hangzhou, China, on June 21. The two-day event, organized by Tsinghua University, brought together over a thousand leaders, experts, and representatives from various sectors related to the energy internet. Over 100,000 viewers also tuned in via live broadcasts on platforms such as Tsinghua University. Conference Explores AI-Energy Integration The energy internet, a core carrier that integrates advanced technologies and intelligent controls, is a driving force for the intelligent upgrading of energy systems and industrial transformation. Themed "Artificial Intelligence Deepens Collaboration, Energy Technology Seeks Innovation," the conference aimed to explore pathways for zero-carbon transitions and the digital energy era. The event was co-hosted by Energy Internet Research Institute,Tsinghua University, People's Government of Xiaoshan District, State Grid Zhejiang Electric Power Company Hangzhou Power Supply Company and China Energy Research Society. Key figures from the National Energy Administration, the State Grid Corporation of China, China Southern Power Grid Co., Ltd., the People's Government of Xiaoshan District in Hangzhou, and Tsinghua University were among the attendees. They delivered speeches at the conference, highlighting the importance of the energy internet in driving sustainable development and innovation in the energy sector. Keynote speeches were delivered by Shi Yigong, president of Westlake University and an academician of the Chinese Academy of Sciences, and Zhang Dongxiao, executive vice president and dean of academic affairs at Easter Institute of Technology, Ningbo and and a member of the US National Academy of Engineering. They emphasized the transformative impact of AI on traditional scientific research and the necessity of combining high-quality data with industry principles to unlock the true value of big data. Senior representatives from State Grid Zhejiang Electric Power Company Hangzhou Power Supply Company, Envision Energy Co., Ltd., and Unitree Robotics, as well as Mei Shengwei, a tenured professor from the Department of Electrical Engineering at Tsinghua University and vice president of Qinghai University, delivered keynote speeches at the conference. The event brought together experts from various fields to discuss the development of China's energy internet industry and technological innovation under the backdrop of the country's "dual carbon" goal. Annual Report Released, Excellence Recognized During the conference, the Energy Internet Research Institute,Tsinghua University and the China Energy Internet Alliance released the "2025 Annual Report: Development of National Energy Internet". The report provides a comprehensive overview of China's energy internet sector, covering hot policies, development trends, and innovation status. It consolidates consensus from various sectors and offers authoritative assessments and strategic foresight for the development of China's energy internet. The conference also recognized projects leading enterprises that won the "2025 Best Energy Internet Practice Case" award and experts who made "outstanding contributions." Six sub-forums were held on June 20, covering topics such as energy digitalization, energy Internet of Things, power carbon neutrality, energy storage applications, artificial intelligence, and new power equipment and engineering applications. On June 21, a comprehensive forum featured discussions on the collaborative development of artificial intelligence and the energy internet. Significance and Future Outlook The conference marked a significant step in China's energy transition, highlighting the role of AI in driving innovation and sustainability. As China accelerates core technology breakthroughs and ecosystem construction, the conference showcased the potential for China to contribute a paradigmatic "China Solution" to global energy development. "It underscored the importance of technological integration in building a green, intelligent, and sustainable energy future," The organizer told Global Times Online. View original content to download multimedia: SOURCE Global Times Online Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store